HOW TO GO FORWARD DR RÉMY DEMEESTER BREACH

LET'S ASK CHATGPT! « WAY FORWARD FOR CARE OF



THE AGEING HIV PATIENTS? »

As the population of people living with HIV (PLHIV) continues to age, it is essential to address the unique challenges and considerations that arise with ageing with HIV. Here are some ways forward for care of the ageing HIV patients:

- 1. Encourage regular health check-ups: Regular check-ups with healthcare providers are essential for ageing PLHIV to monitor their overall health and HIV-related complications. These check-ups should include monitoring of liver and kidney function, bone density, and cardiovascular health.
- 2. Address comorbidities: Ageing PLHIV are at an increased risk of developing comorbidities such as cardiovascular disease, diabetes, and cancer. Thus, healthcare providers should focus on addressing and managing these conditions through lifestyle modifications, medications, and regular monitoring.
- 3. Promote adherence to antiretroviral therapy (ART): Adherence to ART is critical for maintaining viral suppression, which helps reduce the risk of HIV-related complications. Healthcare providers should work with ageing PLHIV to develop strategies to support adherence and address any barriers that may arise.
- 4. Provide social support: Ageing PLHIV may experience social isolation, stigma, and discrimination. Providing social support through peer networks and community-based organizations can help mitigate these challenges and improve their overall well-being.
- 5. Address mental health: Ageing PLHIV may also experience mental health challenges such as depression and anxiety. Thus, healthcare providers should address these issues through counseling, support groups, and referrals to mental health professionals.

In summary, healthcare providers should take a comprehensive and holistic approach to care for ageing PLHIV, focusing on regular health check-ups, addressing comorbidities, promoting adherence to ART, providing social support, and addressing mental health.



GOAL OF MEDICAL CARE: TO PROLONG LIFE AND IMPROVE HEALTH RELATED QUALITY OF LIFE

Major causes of mortality:

- Cancer
- Cardiovascular diseases
- Infectious diseases

Prevention

 \Rightarrow

Adequate testing for early diagnostic




Prompt and optimized treatment

Improve health related quality of life:

- Orthopedic and rhumatologic diseases, metabolic disorders
- Mental health
- Pyschosocial support and multidisciplinary management



CAUSES OF DEATH BY FREQUENCY IN EUROPE



Main causes of death by age and sex, EU, 2020 (standardised death rate per 100 000 inhabitants)

	Men		Women		
	Cause of death	Rate for male inhabitants	Cause of death	Rate for female inhabitants	
Below 65 years old	Lung cancer(1)	20.59	Breast cancer	12.78	
	Accidents	20.22	Lung cancer(1)	10.81	
	Heart attack	15.88	COVID-19(2)	6.31	
	COVID-19(2)	15.02	Colorectal cancer(5)	5.23	
	Chronic liver disease	13.97	Cerebrovascular diseases	5.21	
	Intentional self-harm	13.55	Accidents	4.68	
Age 65 and above	COVID-19(2)	570.53	Cerebrovascular diseases	319.47	
	Cerebrovascular diseases	378.87	COVID-19(2)	311.16	
	Lung cancer(1)	288.85	Dementia	168.51	
	Heart attack	213.65	Heart attack	110.97	
	Chronic lower respiratory diseases	190.29	Breast cancer	108.33	
	Prostate cancer	176.97	Chronic lower respiratory diseases	88.97	

- (1) Malignant neoplasms of the trachea, bronchus and lung
- (2) See section 'Classification of the causes of death' for details on how COVID-19 deaths were calculated.
- (3) Malignant neoplasms of the colon, rectosigmoid junction, rectum, anus and anal canal

Source: Eurostat (online data code: hlth_cd_asdr2)



eurostat 🔼



Source: Eurostat (online data code: hlth_cd_aro)



EACS GUIDELINES: PREVENTION AND MANAGEMENT OF COMORBIDITIES

Prevention:

- Life style interventions (stop tobacco!, *...)
- Vaccination
- Control of the cardiovascular risk factors
- Early diagnosis
- Prompt and optimized treatment

E	3 R	EΑ	СН

Part IV	
Prevention and Management of Co-morbidities	57
Opioid Addiction, Pharmacological Treatment	58
Cancer: Screening Methods	59
Cancer: Treatment Monitoring	60
Lifestyle Interventions	61
Prevention of Cardiovascular Disease (CVD)	62
Hypertension: Diagnosis, Grading and Management	63
Hypertension: Drug Sequencing Management	64
Drug-drug Interactions between Antihypertensives and ARVs	65
Type 2 Diabetes: Diagnosis	67
Type 2 Diabetes: Management	68
Dyslipidaemia	69
Treatment Goal for LDL-c for Very High and High CVD Risk Persons	70
Bone Disease: Screening and Diagnosis	71
Vitamin D Deficiency: Diagnosis and Management	72
Approach to Fracture Reduction	73
Kidney Disease: Definition, Diagnosis and Management	74
ARV-associated Nephrotoxicity	75
Indications and Tests for Proximal Renal Tubulopathy (PRT)	76
Dose Adjustment of ARVs for Impaired Renal Function	77
Work-up and Management of persons with Increased ALT/AST	79
Liver Cirrhosis: Classification and Surveillance	80
Liver Cirrhosis: Management	81
Non-Alcoholic Fatty Liver Disease (NAFLD)	82
Diagnosis and Management of Hepatorenal Syndrome / Acute Kidney Injury (HRS-AKI)	83
Dose Adjustment of ARVs for Impaired Hepatic Function	84
Lipodystrophy and Obesity: Prevention and Management	85
Hyperlactataemia and Lactic Acidosis: Diagnosis, Prevention and Management	87

Travel	88
Drug-drug Interactions between Anti-malarial Drugs and ARVs	89
Vaccination	90
Sexual and Reproductive Health	91
Sexual Dysfunction	94
Treatment of Sexual Dysfunction	95
Mental Health: Depression and Anxiety Disorders	96
Depression: Screening and Diagnosis	96
Depression: Management	97
Classification, Doses, Safety and Adverse Effects of Antidepressants	98
Drug-drug Interactions between Antidepressants and ARVs	99
Anxiety Disorders: Screening and Diagnosis	100
Anxiety Disorders: Management	101
Classification, Doses and Adverse Effects of Anxiolytics	102
Drug-drug Interactions between Anxiolytics and ARVs	103
Algorithm for Diagnosis & Management of Cognitive Impairment without Obvious Confounding Conditions	104
Chronic Lung Disease	105
Drug-drug Interactions between Bronchodilators (for COPD) and ARVs	106
Drug-drug Interactions between Pulmonary Antihypertensives and ARVs	107
Managing Older Persons with HIV	108
Solid Organ Transplantation (SOT)	113
Drug-drug Interactions between Immunosuppressants (for SOT) and ARVs	114


EACS Guidelines | EACSociety

*Prevention: Prévention | Causes du Cancer et Leucémie | Fondation contre le Cancer



GOAL OF MEDICAL CARE: PRIMUM NON NOCERE

- Polypharmacy: check drug drug interactions, secundary effects, adapt doses to impaired renal and hepatic functions
- The best is the enemy of good: security of the patient before applying the last guidelines



Part III Drug-drug Interactions and Other Prescribing Issues Drug-drug Interactions between ARVs and Non-ARVs 27 29 Drug-drug Interactions between Analgesics and ARVs Drug-drug Interactions between Anticoagulants/Antiplatelet Agents Drug-drug Interactions between Antidepressants and ARVs 31 32 Drug-drug Interactions between Antihypertensives and ARVs 34 Drug-drug Interactions between Anti-malarial Drugs and ARVs 35 Drug-drug Interactions between Anti-tuberculosis Drugs and ARVs Drug-drug Interactions between Anxiolytics and ARVs Drug-drug Interactions between Bronchodilators (for COPD) and ARVs Drug-drug Interactions between Contraceptives and ARVs 40 Drug-drug Interactions between Corticosteroids and ARVs Drug-drug Interactions between COVID-19 Therapies and ARVs Drug-drug Interactions between Hormone Replacement Therapy (HRT) Drug-drug Interactions between Immunosuppressants (for SOT and ARVs Drug-drug Interactions between Pulmonary Antihypertensives Drug-drug interactions between Viral Hepatitis Drugs and ARVs 46 Administration of ARVs in persons with Swallowing Difficulties Dose Adjustment of ARVs for Impaired Hepatic Function 50 Dose Adjustment of ARVs for Impaired Renal Function 52 Selected Non-ARV Drugs Requiring Dosage Adjustment in Renal Insufficiency Prescribing in Older Persons with HIV Selected Top 10 Drug Classes to Avoid in Older Persons with HIV Dosage Recommendations for Hormone Therapy when Used at High Doses for Gender Transitioning

Liverpool HIV Interactions (hiv-druginteractions.org)



MULTIDISCIPLINARY APPROACH

- Multidisciplinary team of the HIV Reference Centres
 - Nurse
 - Social worker
 - Psychologist
 - Dietetician

Adapted care and support New approaches to develop

- Collaboration with family doctors
- Collaboration with other specialists (cardiologists, rhumatologists, endocrinologists, nephrologists,...)
- Collaboration to reinforce with geriatric teams to allow ageing PLWH to benefit from their expertise
 - Geriatric day hospital evaluation and management
 - Revalidation

•

INDICATORS: « A PUBLIC HEALTH VALUE-BASED HEALTHCARE PARADIGM FOR HIV »

Provide Patient-Centered HIV Care					
Support patient's quality of life	Support patient's quality of life		of PLWH with good QoL as meas- ured by standardized tool		
	Measure at least once per year QoL	%	of patients in follow-up with QoL being measured each year		
	Provide at least once per year advice for mental wellbeing	# and %	of patients having received sup- port/advice for mental wellbeing		
Prevent and manage comorbid	Prevent and manage comorbidities		Incidence of specific comorbidities per 100 000 population		
Prevention					
	Screening for hiv/treatment- related comorbidities	%	of PLWH being annualy screened for hiv/treatment related comorbidities		
		%	of PLWH with a smoking history documented in the last 2 years		
		%	of PLWH with blood pressure recorded in the last 15 months		
Management					
	Follow-up management of comorbidities	# and %	of PLWH with known comorbidi- ties		
		%	of PLWH with renal function being assessed annualy		



PUBLIC HEALTH APPROACH AND LINK WITH THE HIV PLAN 2020-2026



- "Older people are widely perceived by society, including by health-care professionals, to be
 less at risk of contracting new HIV infections. Because society assumes that older people are
 not sexually active or drug users, there are barriers to access to protective health
 information and early HIV testing".
- "Nearly half of older adults over 50 years of age with HIV are diagnosed late (CD4 <350/µl)".
- ⇒Prevention pillar: "1.3. Update, develop and implement informative and educational tools on HIV/STI prevention and risk reduction for key-populations, including reduction of HIVrelated stigma and discrimination"
- ⇒Testing pillar: identify undiagnosed PLWH also in the ageing population (sentinel diseases, population at increased prevalence, present or past risk factors,...)



PUBLIC HEALTH APPROACH AND LINK WITH THE HIV PLAN 2020-2026



- "Older people with HIV also have higher levels of multimorbidity compared with people of similar age without HIV"
- ⇒ Care pillar: Priority area 4: Guarantee optimal quality of care for PLWH within a holistic approach, including prevention and management of complications and comorbidities
- "People ageing with HIV face an intersection of age-related and HIV-related stigma, which has a traumatic impact on their health-related quality of life".

⇒ Quality of life pillar:

- ⇒ Priority area 1: **Empower PLWH to make healthy lifestyle choices**, enjoy a healthy (sexual) life and assert their rights
- ⇒ Priority area 2: Ensure that health care providers, community health workers and patient organisations are sensitive and responsive to the needs of PLWH
- ⇒ Priority area 3: Ascertain that all PLWH achieve an optimal quality of life, free from stigma and discrimination



« We must continue to build on the results of the success of ART to ensure that ageing with HIV is something to be celebrated, not mourned »

THANK YOU FOR YOUR ATTENTION

